remark
collabor
effort
coordin
sever
acut
respiratori
syndrom
sar
team
result
discoveri
etiolog
agent
sever
acut
respiratori
syndrom
less
month
announc
global
alert
develop
vaccin
prevent
sar
pursu
urgenc
cooper
spirit
sar
highli
lethal
control
first
gener
transmiss
like
becom
endem
region
world
healthcar
infrastructur
underdevelop
epidemiolog
control
measur
weak
scientif
commun
alreadi
learn
mani
import
lesson
hiv
vaccin
develop
heed
exampl
consider
given
develop
vaccin
protect
across
region
strain
sar
newli
emerg
coronaviru
sarscoronaviru
sarscov
prove
variabl
may
mutat
respons
immun
pressur
sarsspecif
research
reagent
also
collect
share
would
includ
sar
peptid
adjuv
dna
vaccin
vector
clinic
grade
viral
vector
rapidli
develop
collabor
approach
develop
sar
vaccin
effect
safe
way
go
articl
review
parallel
hiv
sar
propos
approach
would
acceler
develop
sar
vaccin
due
remark
effort
coordin
sever
acut
respiratori
syndrom
sar
team
understand
clinic
epidemiolog
characterist
etiolog
sever
acut
respiratori
syndrom
achiev
less
month
announc
outbreak
china
result
groundbreak
intern
collabor
know
sar
epidem
due
human
coronaviru
hcov
infect
name
sarscoronaviru
sarscov
sever
sarscoronaviru
genom
map
function
least
protein
determin
genom
avail
genbank
make
possibl
laboratori
around
world
begin
process
build
safe
effect
sar
vaccin
although
much
learn
sar
mani
lesson
alreadi
drawn
experi
hiv
first
lesson
keep
mind
concern
strain
variabl
sar
like
hiv
rna
viru
whose
replic
errorpron
studi
separ
sar
strain
emerg
singl
point
sourc
suggest
pattern
evolut
respons
immun
pressur
much
like
evolut
hiv
form
coronavirusmurin
hepat
viru
particularar
known
mutat
escap
host
immun
respons
clade
strain
sar
emerg
hiv
sar
vaccin
research
abl
develop
vaccin
adequ
address
problem
hiv
vaccin
develop
slow
address
hiv
variabl
scientist
involv
sar
vaccin
effort
must
address
issu
promptli
import
hiv
vaccin
develop
effort
initi
focus
replic
approach
use
develop
hepat
b
vaccin
develop
clone
express
surfac
protein
viru
simplist
approach
complex
viru
recent
proven
failur
scientist
pursu
quick
easi
solut
hope
stimul
protect
antibodi
respons
despit
exist
evid
coronaviru
vaccin
anim
base
spike
surfac
protein
larg
ineffect
order
best
defin
effect
sar
vaccin
approach
import
consid
correl
protect
coronavirus
anim
model
evid
immun
may
emerg
clinic
experi
littl
known
yet
human
immun
respons
sarscov
much
learn
examin
immunolog
coronavirus
histori
coronaviru
vaccin
must
also
examin
hostpathogen
interact
ask
whether
specif
antigen
protein
deriv
pathogen
host
respons
antibodi
cell
respons
provid
insight
type
vaccin
develop
sar
like
hiv
potenti
set
global
pandem
articl
argu
much
learn
pastboth
term
build
cooper
approach
order
expedit
develop
effect
vaccin
term
scientif
knowledg
emerg
result
collabor
process
better
time
begin
work
new
sar
vaccin
imper
captur
moment
viru
rel
new
clade
strain
highli
virul
airborn
viru
emerg
coronaviru
common
worldwid
pathogen
infect
varieti
mammal
bird
viru
classifi
three
group
sarscov
assign
fourth
group
unlik
exist
coronavirus
coronaviru
expert
particip
meet
sar
recent
held
nih
reach
follow
consensu
sarscov
like
group
includ
bovin
murin
coronavirus
coronavirus
positivestrand
singlestrand
rna
virus
belong
order
nidoviral
also
includ
famili
arterivirida
coronavirida
ronivirida
coronavirida
famili
contain
genus
coronaviru
toroviru
genu
coronaviru
broken
three
group
sarscov
assign
fourth
group
see
fig
human
coronaviru
infect
hcov
season
gener
manifest
wintertim
respiratori
infect
enter
infect
mostli
infant
month
adult
infect
less
common
infect
among
children
hcov
also
rare
caus
neurolog
syndrom
reinfect
appear
common
even
though
antigen
variat
limit
spike
protein
given
full
extent
hcov
variat
yet
determin
possibl
variat
nonstructur
protein
may
allow
escap
immun
phenomenon
observ
coronavirus
murin
hepat
viru
contrast
hcov
reinfect
sarscov
appear
rel
rare
least
one
case
accord
investig
report
hong
kong
recent
nih
confer
sar
reoccurr
associ
milder
form
ill
reinfect
case
commoncold
coronaviru
impli
either
immun
incomplet
antigen
variat
imped
develop
immun
low
rate
reinfect
base
avail
data
observ
sar
high
rate
recoveri
acut
ill
absenc
effect
medic
therapi
approxim
young
adult
recov
suggest
protect
diseas
achiev
rais
hope
develop
vaccin
howev
escap
mutat
respons
immun
pressur
observ
hiv
select
point
mutat
known
caus
major
shift
pathogen
coronavirus
well
tissu
specif
fact
viru
famous
difficult
replic
without
error
abl
toler
larg
reduct
well
point
mutat
genom
suggest
variat
sequenc
sar
expect
epidem
continu
move
human
popul
much
observ
hiv
accordingli
evolut
strain
variabl
identif
conserv
crossstrain
epitop
need
monitor
develop
sarscov
vaccin
emerg
new
strain
monitor
influenza
genom
coronaviru
believ
respons
global
outbreak
sar
sequenc
amplif
short
region
polymeras
gene
strongli
conserv
part
coronaviru
genom
rtpcr
nucleotid
sequenc
reveal
sar
viru
novel
coronaviru
previous
present
human
popul
conclus
confirm
serolog
investig
sarscoronaviru
appear
novel
coronaviru
fall
midway
cat
human
speci
although
mani
coronaviru
expert
believ
closer
group
coronaviru
bovin
cov
mhv
sarscov
genom
nucleotid
length
genom
organ
similar
coronavirus
eleven
open
read
frame
correspond
known
coronaviru
protein
includ
polymeras
protein
polymeras
spike
protein
small
membran
protein
e
membran
protein
nucleocapsid
protein
n
identifi
fig
open
read
frame
believ
encod
mani
separ
protein
known
unknown
function
nonstructur
protein
seem
encod
first
half
genom
wherea
structur
protein
spike
membran
envelop
nucleocapsid
locat
second
half
genom
mutat
genom
alreadi
describ
accord
recent
report
compar
sar
genom
link
common
point
sourc
despit
limit
amount
time
elaps
primari
transmiss
hotel
develop
secondari
case
singapor
less
month
total
amino
acid
sequenc
mutat
rna
polymeras
spike
glycoprotein
membran
nucleocapsid
sever
uncharacter
put
protein
identifi
fig
one
particular
amino
acid
chang
posit
genom
isoleucin
residu
chang
threonin
nonconserv
amino
acid
chang
region
spike
protein
observ
modif
occur
carriag
sarscov
hong
kong
hotel
singapor
one
patient
may
allow
viru
escap
immun
respons
mutat
previous
observ
mhv
spike
protein
respons
pressur
cellmedi
immun
respons
mutat
larg
genom
base
respons
immun
pressur
omin
sign
futur
vaccin
develop
sarscov
indic
may
see
degre
variat
sar
genom
match
exce
hiv
common
report
clinic
present
sar
base
hospit
patient
fever
half
person
affect
report
gener
influenzalik
symptom
chill
malais
gastrointestin
symptom
loss
appetit
myalgia
mean
incub
period
sar
estim
day
case
fatal
rate
high
patient
younger
year
higher
patient
age
year
older
nearli
patient
develop
respiratori
failur
requir
assist
ventil
case
occur
within
day
infect
guandong
case
occur
within
day
singl
pointexposur
unfortun
given
clinic
manifest
sar
allow
readi
distinct
common
respiratori
viral
infect
diagnosi
sar
may
becom
difficult
epidemiolog
link
travel
select
area
diminish
time
rapid
accur
diagnost
tool
critic
manag
epidem
tool
avail
may
discov
hiv
inde
mani
person
infect
yet
manifest
illnessin
word
hospit
patient
may
repres
tip
iceberg
diagnost
test
sar
current
limit
antibodi
assay
depend
develop
ab
thu
detect
infect
possibl
day
follow
infect
pcr
assay
sensit
technic
difficult
set
like
falseneg
earli
day
infect
transmiss
occur
droplet
transmiss
may
also
occur
fecal
oral
rout
although
food
yet
suspect
mean
transmiss
current
outbreak
sarscov
detect
time
clinic
present
persist
throughout
acut
ill
decreas
convalesc
accord
report
investig
speak
nih
confer
sar
respiratori
secret
still
pcr
posit
viru
cultur
day
present
stool
sampl
anim
coronaviru
infect
protein
spike
promin
transmembran
protein
two
domain
determin
speci
tissu
specif
coronaviru
modif
associ
chang
type
cell
target
viru
epitheli
cell
line
respiratori
tract
appear
repres
main
target
sar
although
hepat
renal
cardiac
ophthalm
tissu
may
infect
coronavirus
coronavirus
also
report
infect
macrophag
cours
hcov
respiratori
infect
growth
viru
infect
cell
appear
local
epithelium
upper
respiratori
tract
sarscov
contrast
appear
affect
cell
line
lower
respiratori
tract
even
though
growth
human
cell
line
common
featur
coronavirus
sar
viru
grown
vero
cell
fibroblast
cell
line
sarscov
infect
result
cytopath
effect
bud
coronaviruslik
particl
endoplasm
reticulum
within
infect
cell
sarscov
infect
mice
accord
cdc
investig
speak
nih
confer
infect
scid
host
target
cell
rang
target
cell
receptor
sarscov
remain
discov
time
final
due
limit
host
cell
rang
viru
adequ
anim
model
sarscov
found
current
sar
outbreak
believ
origin
china
late
issu
global
alert
emerg
sever
acut
respiratori
syndrom
march
five
death
report
time
immedi
grave
concern
rapid
spread
diseas
within
week
countri
also
report
case
total
case
includ
chines
case
respons
develop
cdc
issu
interim
guidanc
concern
infect
control
precaut
healthcar
commun
set
rais
concern
intern
travel
despit
precaut
number
person
countri
affect
continu
climb
may
report
cumul
total
probabl
case
death
countri
http
wwwwhointcsren
fig
healthcar
worker
increasingli
affect
sar
recent
reemerg
sar
canada
clearli
link
nosocomi
transmiss
local
epidem
contain
sound
barrier
precaut
good
reason
believ
sar
becom
endem
outbreak
recur
fall
winter
transmiss
season
one
reason
believ
sar
becom
endem
transmiss
viru
continu
unab
region
outsid
larger
citi
china
may
nine
region
china
qualifi
categori
b
second
gener
c
epidemiolog
unlink
transmiss
pattern
c
transmiss
mainli
occur
region
outsid
larger
citi
inner
mongolia
write
case
sar
describ
africa
india
south
america
impact
arriv
sar
spread
airborn
fecalor
rout
region
world
crowd
citi
poor
sanit
fragil
healthcar
infrastructur
fact
life
like
reveal
next
month
hiv
uncontrol
transmiss
expect
occur
region
world
access
healthcar
poor
understand
basic
precept
infecti
diseas
transmiss
extrem
limit
transmiss
pattern
c
case
may
due
asymptomat
shedder
sar
viru
canadian
chines
physician
report
assembl
scientist
nih
confer
sar
least
contact
canada
number
case
hong
kong
show
evid
infect
seroconvers
report
symptom
thu
number
total
infect
asymptomat
shedder
includ
may
much
higher
previous
report
furthermor
serolog
evid
infect
observ
rang
small
anim
suggest
anim
reservoir
may
exist
would
mean
complet
erad
viru
quarantin
may
difficult
achiev
inform
avail
immun
correl
protect
sar
thu
forc
extrapol
avail
clinic
inform
inform
glean
studi
coronaviru
infect
anim
sever
aspect
clinic
present
sar
deserv
mention
first
individu
recov
infect
appear
relationship
recoveri
declin
viral
load
suggest
immun
acquir
offer
great
promis
develop
effect
vaccin
second
anecdot
report
individu
seroconvert
never
report
ill
indic
immun
infect
occur
rapidli
exposur
individu
moreov
ill
may
prevent
third
elderli
individu
observ
highest
mortal
rate
greater
higher
mortal
rate
older
individu
may
due
limit
abil
gener
new
b
cell
respons
contain
new
infect
summari
immun
sar
achiev
ill
may
prevent
lastli
clinic
present
sar
subacut
unlik
infecti
diseas
except
chronic
viral
diseas
like
hiv
hepat
c
sar
character
long
day
prodrom
phase
gradual
climb
viral
load
peak
around
day
declin
viral
load
day
symptom
improvefor
individu
recov
ill
studi
contrast
patient
recov
yet
perform
immun
respons
may
contain
possibl
also
exacerb
sar
cell
respons
would
expect
present
soon
day
infect
antibodi
seroconvers
shown
occur
around
day
symptom
exacerb
antibodymedi
exacerb
observ
two
separ
coronavir
diseas
anim
felin
infecti
periton
bovin
coronavirusassoci
ship
fever
see
current
accept
clinic
intervent
sar
aggress
suppress
local
immun
respons
use
high
dose
inhal
steroid
ribivarin
also
use
known
modul
immun
respons
may
direct
effect
sar
viru
cellmedi
humor
immun
respons
associ
exacerb
diseas
coronaviru
infectionsthes
advers
effect
must
care
consid
design
vaccin
exampl
case
murin
hepat
viru
mhv
group
coronaviru
diseas
cell
respons
protect
cell
type
implic
demyelin
brain
spinal
cord
follow
infect
neurotrop
mhv
antibodi
respons
may
also
detriment
set
infecti
bronchiti
viru
ibv
chickensalthough
incomplet
evid
bird
low
level
humor
immun
measur
antibodi
titer
tear
wors
higher
level
humor
immun
respons
also
link
humor
respons
bovin
viral
diarrhea
viru
develop
ship
fever
attribut
bovin
respiratori
coronaviru
cattl
feedlot
correl
protect
coronaviru
diseas
studi
anim
model
coronaviru
expert
emphas
wide
rang
coronaviru
diseas
clinic
manifest
diseas
correl
protect
vari
wide
pathogen
anim
model
humor
cellular
immun
respons
contribut
protect
coronaviru
diseas
anim
model
set
antibodi
cell
contribut
exacerb
patholog
although
mechan
occur
well
understood
role
versu
humor
respons
hotli
debat
coronaviru
infect
mhv
bocv
bovin
coronaviru
also
group
cell
critic
protect
ill
cell
helper
cytotox
cell
ctl
respect
involv
cell
immun
also
requir
protect
porcin
endem
diarrhea
viru
pedv
humor
cellmedi
immun
involv
immun
respons
turkey
coronaviru
infect
tcov
infecti
bronchiti
viru
devast
diseas
chicken
produc
focu
mani
vaccin
studi
cell
appear
involv
protect
immun
respons
ibv
also
import
note
crossviru
cell
immun
exist
describ
japanes
enceph
viru
jev
west
nile
viru
wnv
anim
model
exampl
pig
expos
porcin
respiratori
coronaviru
prcv
protect
virul
transmiss
gastroenter
viru
vte
protect
immun
respons
attribut
cell
protect
correl
cell
prolifer
evid
mhv
cell
requir
erad
infect
antibodi
involv
reduc
viral
load
acut
infect
differ
may
relat
abil
coronavirus
form
syncitia
note
syncitialik
giant
cell
observ
lung
tissu
specimen
deriv
sar
patient
celltocel
transmiss
via
syncitia
format
also
occur
sar
erad
sarscov
may
also
achiev
humor
respons
alon
therefor
cell
immun
may
requir
clear
infect
number
laboratori
map
cell
epitop
coronaviru
infect
exampl
cell
epitop
identifi
nucleocapsid
protein
mhv
nucleocapsid
avian
coronaviru
tgev
swine
persist
infect
case
mhv
seem
due
ctl
escap
mutat
viral
genom
abrog
abil
cellular
immun
system
stimul
ctl
respons
mutat
occur
even
mhv
spike
protein
respons
pressur
cellmedi
immun
respons
escap
ctl
respons
may
allow
mhv
persist
cn
mhvspecif
ctl
respons
polyclon
ctl
escap
occur
nonetheless
type
mutat
respons
immun
pressur
observ
coronavirus
highli
reminisc
ctl
escap
observ
cours
hiv
infect
sinc
sarscov
like
hiv
rna
viru
errorpron
replic
mechan
reason
concern
variant
sarscov
escap
cellular
immun
respons
may
also
evolv
mutat
sarscov
genom
protein
may
occur
respons
immun
pressur
describ
likelihood
develop
safe
effect
vaccin
sarscov
high
peopl
becom
immun
surviv
diseas
defin
correl
immun
survivor
abl
make
vaccin
one
approach
develop
safe
effect
vaccin
would
map
cell
epitop
recogn
sar
survivor
conserv
across
strain
sarscov
clone
epitop
vaccin
vector
demonstr
proof
immunogen
human
immun
system
hla
transgen
mice
prior
test
vaccin
sar
patient
normal
volunt
live
attenu
coronaviru
vaccin
made
delet
group
specif
gene
specif
groupsdelet
gene
alter
replic
attenu
viru
live
attenu
ibv
vaccin
combin
inactiv
ibv
good
success
broiler
chicken
live
attenu
vaccin
also
made
use
tradit
method
consist
passag
viru
obtain
one
speci
anim
pig
cell
deriv
anoth
speci
cattl
gener
fact
live
attenu
vaccin
significantli
effect
whole
kill
vaccin
anim
diseas
suggest
develop
cellmedi
immun
critic
protect
coronavirus
howev
great
concern
vaccin
strain
could
recombin
wild
type
circul
strain
unlik
fda
approv
use
live
attenu
sarscov
vaccin
human
without
extens
evid
recombin
revers
virul
occur
whole
kill
vaccin
common
anim
food
industri
gener
safe
cheap
produc
autolog
vaccin
vaccin
develop
viru
circul
specif
herd
cattl
group
chicken
often
use
limit
licens
issu
allow
use
vaccin
specif
geograph
region
approach
use
coronavirus
bocv
ibv
signific
pathogen
cattl
chicken
whole
kill
bovin
coronaviru
vaccin
develop
cattl
appear
safe
effect
inactiv
canin
coronaviru
vaccin
avail
protect
canin
coronaviru
young
dog
howev
clear
kill
vaccin
protect
differ
strain
canin
coronaviru
vaccin
underutil
veterinari
industri
comparison
vaccin
prevent
ibv
live
attenu
vaccin
appear
much
effect
whole
kill
vaccin
recombin
subunit
vaccin
use
molecular
biolog
techniqu
produc
larg
quantiti
recombin
viral
protein
likewis
expect
limit
abil
protect
virus
evolv
human
popul
immun
pressur
caus
signific
variat
viral
genom
recombin
technolog
certainli
permit
rapid
develop
sar
spike
proteinbas
vaccineeffort
alreadi
underway
produc
protein
safelyth
need
cell
immun
shown
mhv
bocv
two
relat
virus
descript
region
variabl
earli
epidem
point
fact
approach
need
supplement
cellmedi
immunitydirect
vaccin
relev
whole
sar
genom
recombin
fowlpox
contain
gene
ibv
produc
shown
rel
protect
ibv
fowlpox
viru
express
c
termin
nucleocapsid
protein
ibv
also
develop
construct
protect
challeng
homolog
strain
crossstrain
protect
also
observ
crossstrain
protect
may
due
effect
present
conserv
ctl
epitop
viral
vector
dna
vaccin
contain
nucleoprotein
gene
porcin
transmiss
gastroenter
viru
ptgv
use
vaccin
gastroenteritisboth
humor
cellmedi
immun
respons
induc
note
offici
rais
concern
coronaviru
variat
make
difficult
develop
singl
vaccin
base
spike
protein
flu
may
becom
necessari
updat
vaccin
would
requir
similar
global
surveil
vector
approach
dna
viral
vector
current
highli
favor
coronaviru
expert
dna
prime
adenoviru
mva
boost
approach
current
explor
hiv
vaccin
develop
might
avenu
worth
explor
sar
pathogen
multival
multi
gene
mix
humor
cellmedi
approach
strongli
support
coronaviru
expert
sinc
anim
model
point
involv
one
arm
immun
system
epitop
easili
deliv
context
dna
viral
vector
epitopedriven
approach
coronaviru
vaccin
develop
alreadi
attempt
success
one
advantag
epitop
base
approach
region
sarscov
genom
may
similar
self
therefor
associ
potenti
autoimmun
effectscan
elimin
epitopebas
approach
would
avoid
possibl
revers
virul
may
better
abl
avoid
type
vaccineinduc
enhanc
diseas
appear
associ
vaccin
bocv
fipv
mhv
cellmedi
immunitydirect
vaccin
highli
unlik
recombin
statement
true
epitopebas
vaccin
least
true
live
attenu
vaccin
could
also
use
treatment
sar
method
use
hiv
vaccin
could
provid
ethic
appropri
avenu
test
safe
epitopebas
sar
vaccin
human
variat
lead
escap
subunit
whole
kill
vaccin
prime
one
strain
viru
efficaci
variant
virus
may
lower
sar
evolv
hiv
develop
viral
variabl
may
preclud
use
singl
strain
sarscov
vaccin
one
mean
solv
problem
variabl
search
conserv
epitop
conserv
across
strain
sarscov
epitop
highli
mutabl
protect
sarscov
viru
evolv
may
make
select
epitop
highli
conserv
hiv
vaccin
develop
relev
much
learn
hiv
vaccin
effort
previou
studi
coronaviru
vaccin
anim
applic
sar
worrisom
similar
sarscov
hiv
rna
virus
abl
mutat
select
pressur
host
coronavirus
especi
prone
mutat
recombin
sarscov
sequenc
alreadi
uncov
evid
mutat
respons
immun
pressur
select
multipl
highli
conserv
achil
heel
epitop
sar
immunom
done
least
one
hiv
vaccin
prototyp
permit
develop
vaccin
remain
relev
sarscov
evolv
humor
cellmedi
immun
respons
may
requir
protect
sarscov
howev
evid
anim
studi
humor
respons
coronavirus
contribut
host
patholog
role
antibodi
exacerb
diseas
sar
yet
defin
role
antibodi
clarifi
vaccin
direct
elicit
humor
immun
need
evalu
potenti
exacerb
diseas
crossreact
cell
respons
also
implic
host
patholog
mhv
model
therefor
develop
celldirect
vaccin
compos
cell
epitop
way
crossreact
host
may
safest
approach
consider
might
also
given
combin
celldirect
vaccin
whole
recombin
vector
spike
protein
vaccin
vaccin
prove
safe
efficaci
immun
respons
recov
convalesc
sar
patient
provid
import
measur
immun
sar
vaccin
design
immun
respons
patient
use
direct
develop
vaccin
conclus
develop
sar
vaccin
pursu
utmost
urgenc
sar
highli
lethal
like
becom
endem
underdevelop
region
world
pathway
vaccin
develop
take
advantag
collect
expertis
vaccin
develop
commun
make
avail
vaccin
compon
vector
deliveri
vehicl
previous
evalu
human
clinic
trial
expedit
develop
vaccin
research
reagent
also
collect
share
would
includ
sar
peptid
adjuv
dna
vaccin
vector
clinic
grade
viral
vector
much
learn
hiv
vaccin
effort
mar
grandstand
poor
cooper
rapidli
develop
collabor
approach
develop
sar
vaccin
effect
safe
best
way
address
newli
emerg
infecti
diseas
nation
institut
allergi
infecti
diseas
niaid
nih
provid
access
sever
hundr
sar
microarray
charg
scientif
commun
distribut
genechip
brand
sar
array
made
affymetrix
inc
coordin
niaid
pathogen
function
genom
resourc
center
pfgrc
sar
array
request
via
webbas
applic
process
found
http
wwwniaidnihgovdmid
genomespfgrcdefaulthtm
video
document
morn
afternoon
plenari
session
nation
institut
health
research
colloquium
sever
acut
respiratori
syndrom
may
avail
http
wwwvideocastnihgovram
real
player
requir
powerpoint
present
morn
afternoon
session
also
post
niaid
web
site
access
http
wwwniaidnihgovsar
meet
htm
